Masato Chiba

In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results

Masayo Yamazaki, William Neway, Tomoyuki Ohe et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 237 citations

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

T. Koga, Kenichi Suda, Toshio Fujino et al. · Journal of Thoracic Oncology · 2021 · 231 citations · Full text

Vitro Experiments, Kras Secondary Mutations, Novel Therapy +9

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Toshio Fujino, Yoshihisa Kobayashi, Kenichi Suda et al. · Journal of Thoracic Oncology · 2019 · 171 citations · Full text

Medicine, Pharmacology, Cancer Genomics +8

Prediction of Hepatic Clearance and Availability by Cryopreserved Human Hepatocytes: An Application of Serum Incubation Method

Yoshihiro Shibata, Hiroyuki Takahashi, Masato Chiba et al. · Drug Metabolism and Disposition · 2002 · 168 citations

Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.

Jiunn H. Lin, Masato Chiba, Suresh K. Balani et al. · Drug Metabolism and Disposition · 1996 · 153 citations